ChartMill · Oct 27, 2026
After-Hours Market Movers for Oct. 27, 2026: Gainers and Losers
After the Oct. 27, 2026 US session, SNTI and NEXR led after-hours gainers, while SCKT and SHFSW led decliners, with deal, earnings, and listing news noted.
RA
NASDAQ · RAPP
Rapport Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$27.54
Down-$4.76 (-17.30%)
Updated Oct 28, 2026, 3:36 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.05B
- P/E ratio
- -111.89
- Dividend yield
- 0.00%
- 52-week range
- $24.69 – $52.93
- Volume
- 703.93K
- Avg. volume
- 522.83K
Price performance · RAPP
RAPP price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 27, 2026
RAPP closed at $27.54 after 21 trading sessions, down 16.60% for the selected period.
- Last close
- $27.54
- Period change
- -16.60%
- Period low
- $25.06
- Period high
- $33.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 27, 2026 | $25.11 | $28.31 | $25.11 | $27.54 | 703.93K |
| Oct 26, 2026 | $26.02 | $27.9499 | $25.08 | $25.33 | 1.04M |
| Oct 23, 2026 | $27.54 | $27.756 | $25.705 | $25.93 | 1.19M |
| Oct 22, 2026 | $26.17 | $27.89 | $25.805 | $26.53 | 1.46M |
| Oct 21, 2026 | $29.91 | $29.91 | $24.69 | $25.06 | 2.16M |
| Oct 20, 2026 | $30.33 | $31.31 | $26.73 | $29.37 | 8.21M |
| Oct 19, 2026 | $27.57 | $29.10 | $27.57 | $28.60 | 300.73K |
| Oct 16, 2026 | $29.50 | $29.745 | $26.925 | $27.57 | 413.61K |
| Oct 15, 2026 | $29.12 | $30.48 | $28.675 | $29.57 | 334.9K |
| Oct 14, 2026 | $28.71 | $29.31 | $28.10 | $28.33 | 304.02K |
| Oct 13, 2026 | $30.00 | $30.01 | $28.6828 | $28.99 | 309.98K |
| Oct 12, 2026 | $30.65 | $30.99 | $30.00 | $30.15 | 127.13K |
| Oct 9, 2026 | $29.73 | $31.20 | $29.5002 | $30.65 | 247.91K |
| Oct 8, 2026 | $30.62 | $30.62 | $29.45 | $29.85 | 236.78K |
| Oct 7, 2026 | $30.81 | $31.35 | $30.455 | $30.86 | 314.99K |
| Oct 6, 2026 | $32.92 | $34.00 | $30.01 | $31.15 | 235.74K |
| Oct 5, 2026 | $32.22 | $32.705 | $31.53 | $32.19 | 198.87K |
| Oct 2, 2026 | $33.33 | $34.48 | $31.77 | $32.17 | 277.63K |
| Oct 1, 2026 | $33.52 | $34.315 | $32.80 | $32.83 | 326.78K |
| Sep 30, 2026 | $33.17 | $34.05 | $32.62 | $33.60 | 582.03K |
| Sep 29, 2026 | $33.25 | $33.66 | $32.12 | $33.02 | 626.15K |
Latest RAPP news
The latest Smart Investors Daily articles mentioning RAPP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RAPP research
Overview
Company profile and research snapshot.
Company profile
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $42.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Jones Trading | Buy | — |
| Oct 21, 2026 | Wells Fargo | Overweight | — |
| Oct 21, 2026 | Guggenheim | Buy | — |
| Oct 20, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 20, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced separate underwritten public offerings of $200.0 million of shares of its common stock (the “common stock offering”) and $150.0 million aggregate principal a
Yahoo · Oct 25, 2026
Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics (NASDAQ:RAPP) reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and supporting plans to advance the candidate into Phase III development. The three-week, plac
Yahoo · Oct 23, 2026
Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data
Rapport Therapeutics (RAPP) moved into focus after reporting that lead candidate RAP-219 met its primary endpoint in a Phase 2 trial for acute bipolar I mania, with statistically significant efficacy and a favorable tolerability profile. Rapport Therapeutics' latest update landed after a choppy stretch. The 1-day share price return of 5.9% contrasts with a 7-day move that declined 10.3% and a 30-day share price return that fell 36.0%, even though the 1-year total shareholder return is still...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
